IL292353A - Anti-haemagglutinin antibodies and methods of using them - Google Patents

Anti-haemagglutinin antibodies and methods of using them

Info

Publication number
IL292353A
IL292353A IL292353A IL29235322A IL292353A IL 292353 A IL292353 A IL 292353A IL 292353 A IL292353 A IL 292353A IL 29235322 A IL29235322 A IL 29235322A IL 292353 A IL292353 A IL 292353A
Authority
IL
Israel
Prior art keywords
antigen
antibody
influenza
binding fragment
administered
Prior art date
Application number
IL292353A
Other languages
English (en)
Hebrew (he)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of IL292353A publication Critical patent/IL292353A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
IL292353A 2019-10-28 2020-10-28 Anti-haemagglutinin antibodies and methods of using them IL292353A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962926914P 2019-10-28 2019-10-28
US202063094170P 2020-10-20 2020-10-20
PCT/US2020/057635 WO2021086899A1 (en) 2019-10-28 2020-10-28 Anti-hemagglutinin antibodies and methods of use thereof

Publications (1)

Publication Number Publication Date
IL292353A true IL292353A (en) 2022-06-01

Family

ID=73498317

Family Applications (1)

Application Number Title Priority Date Filing Date
IL292353A IL292353A (en) 2019-10-28 2020-10-28 Anti-haemagglutinin antibodies and methods of using them

Country Status (13)

Country Link
US (2) US11773156B2 (cg-RX-API-DMAC7.html)
EP (1) EP4051707A1 (cg-RX-API-DMAC7.html)
JP (1) JP7611908B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220088446A (cg-RX-API-DMAC7.html)
CN (2) CN114761428B (cg-RX-API-DMAC7.html)
AU (2) AU2020374878B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022007923A2 (cg-RX-API-DMAC7.html)
CL (1) CL2022001067A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022005281A2 (cg-RX-API-DMAC7.html)
IL (1) IL292353A (cg-RX-API-DMAC7.html)
MY (1) MY207220A (cg-RX-API-DMAC7.html)
PH (1) PH12022550963A1 (cg-RX-API-DMAC7.html)
WO (1) WO2021086899A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4508077A4 (en) 2022-04-14 2026-03-25 Invisishield Tech Ltd COMPOSITIONS FOR PREVENTING OR TREATMENT OF INFLUENZA INFECTIONS

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
EP1740946B1 (en) 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
ATE537190T1 (de) 2006-06-02 2011-12-15 Regeneron Pharma Hochaffine antikörper gegen den humanen il-6- rezeptor
TWI507525B (zh) 2009-06-26 2015-11-11 Regeneron Pharma 具天然免疫球蛋白形式之易分離的雙專一性抗體
SG183149A1 (en) 2010-02-08 2012-09-27 Regeneron Pharma Common light chain mouse
JP6170507B2 (ja) * 2012-01-31 2017-07-26 国立大学法人大阪大学 B型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法
HUE037659T2 (hu) * 2012-03-16 2018-09-28 Regeneron Pharma Hisztidinmódosított könnyûlánc antitestek és genetikailag módosított rágcsálók ennek az elõállítására
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
US10639370B2 (en) 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
AU2015214146B2 (en) * 2014-02-04 2020-09-17 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
MX2016012530A (es) * 2014-03-27 2017-01-05 Genentech Inc Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso.
WO2016011035A2 (en) * 2014-07-15 2016-01-21 Medlmmune, Llc Neutralizing anti-influenza b antibodies and uses thereof
TWI701258B (zh) * 2014-12-19 2020-08-11 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
MX389708B (es) * 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
AU2016270147B2 (en) 2015-06-03 2018-08-23 Xiamen University Broad-spectrum monoclonal anti-flu B antibody and uses thereof
EP3471767A4 (en) * 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai Influenza virus hemagglutinin proteins and uses thereof
WO2018187706A2 (en) * 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
SG11202006379UA (en) * 2018-01-26 2020-07-29 Regeneron Pharma Human antibodies to influenza hemagglutinin

Also Published As

Publication number Publication date
BR112022007923A2 (pt) 2022-07-26
CN122521584A (zh) 2026-08-07
MY207220A (en) 2025-02-06
JP7611908B2 (ja) 2025-01-10
AU2025271140A1 (en) 2026-01-22
WO2021086899A1 (en) 2021-05-06
CO2022005281A2 (es) 2022-05-10
EP4051707A1 (en) 2022-09-07
KR20220088446A (ko) 2022-06-27
CA3153944A1 (en) 2021-05-06
CN114761428B (zh) 2026-05-22
US11773156B2 (en) 2023-10-03
JP2022553703A (ja) 2022-12-26
PH12022550963A1 (en) 2023-09-25
AU2020374878B2 (en) 2025-10-16
US20210171612A1 (en) 2021-06-10
US20240083983A1 (en) 2024-03-14
CN114761428A (zh) 2022-07-15
AU2020374878A1 (en) 2022-04-28
CL2022001067A1 (es) 2023-01-27

Similar Documents

Publication Publication Date Title
US11453714B2 (en) Human antibodies to influenza hemagglutinin
US11117955B2 (en) Anti-Zika virus antibodies and methods of use
AU2016211783A1 (en) Human antibodies to Ebola virus glycoprotein
CN114057869A (zh) 针对中东呼吸综合征-冠状病毒刺突蛋白的人抗体
US11780907B2 (en) Human antibodies to influenza hemagglutinin
AU2025271140A1 (en) Anti-hemagglutinin antibodies and methods of use thereof
EA046393B1 (ru) Антитела к гемагглютинину и их применение
EA044791B1 (ru) Человеческие антитела к гемагглютинину вируса гриппа